Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria : An individual patient data meta-analysis'
© 2024, Sharma et al..
A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥16 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is insufficient for radical cure, and that a higher 450 mg dose could reduce P. vivax recurrences substantially (Watson et al., 2022). In this response, we challenge Watson et al.'s assertion based on empirical evidence from dose-ranging and pivotal studies (published) as well as real-world evidence from post-approval studies (ongoing, therefore currently unpublished). We assert that, collectively, these data confirm that the benefit-risk profile of a single 300 mg dose of tafenoquine, co-administered with chloroquine, for the radical cure of P. vivax malaria in patients who are not G6PD-deficient, continues to be favourable where chloroquine is indicated for P. vivax malaria. If real-world evidence of sub-optimal efficacy in certain regions is observed or dose-optimisation with other blood-stage therapies is required, then well-designed clinical studies assessing safety and efficacy will be required before higher doses are approved for clinical use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
eLife - 13(2024) vom: 07. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Raman [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.02.2024 Date Revised 12.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7554/eLife.89263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368130029 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368130029 | ||
| 003 | DE-627 | ||
| 005 | 20240212232113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.89263 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1289.xml |
| 035 | |a (DE-627)NLM368130029 | ||
| 035 | |a (NLM)38323802 | ||
| 035 | |a (PII)e89263 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Raman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria |b An individual patient data meta-analysis' |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2024 | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024, Sharma et al. | ||
| 520 | |a A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥16 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is insufficient for radical cure, and that a higher 450 mg dose could reduce P. vivax recurrences substantially (Watson et al., 2022). In this response, we challenge Watson et al.'s assertion based on empirical evidence from dose-ranging and pivotal studies (published) as well as real-world evidence from post-approval studies (ongoing, therefore currently unpublished). We assert that, collectively, these data confirm that the benefit-risk profile of a single 300 mg dose of tafenoquine, co-administered with chloroquine, for the radical cure of P. vivax malaria in patients who are not G6PD-deficient, continues to be favourable where chloroquine is indicated for P. vivax malaria. If real-world evidence of sub-optimal efficacy in certain regions is observed or dose-optimisation with other blood-stage therapies is required, then well-designed clinical studies assessing safety and efficacy will be required before higher doses are approved for clinical use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a haemolysis | |
| 650 | 4 | |a human | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a microbiology | |
| 650 | 4 | |a plasmodium vivax malaria | |
| 650 | 4 | |a radical cure | |
| 650 | 4 | |a tafenoquine | |
| 650 | 7 | |a Aminoquinolines |2 NLM | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 650 | 7 | |a Primaquine |2 NLM | |
| 650 | 7 | |a MVR3634GX1 |2 NLM | |
| 650 | 7 | |a tafenoquine |2 NLM | |
| 650 | 7 | |a 262P8GS9L9 |2 NLM | |
| 700 | 1 | |a Chen, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Rolfe, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Fiţa, Ioana-Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Siôn |e verfasserin |4 aut | |
| 700 | 1 | |a Pingle, Anup |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, Rachel A |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Navin |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Hema |e verfasserin |4 aut | |
| 700 | 1 | |a Bird, Panayota |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t eLife |d 2012 |g 13(2024) vom: 07. Feb. |w (DE-627)NLM221831460 |x 2050-084X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g day:07 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7554/eLife.89263 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |b 07 |c 02 | ||